CJC-1295 & Ipamorelin vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295 & Ipamorelin
The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.
Full details →Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 & Ipamorelin | Tirzepatide |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors to sustain GH signaling and extend the half-life of growth hormone release. Ipamorelin triggers strong GH pulses by binding to ghrelin receptors. Together, they create both sustained and pulsatile GH release patterns that more closely mimic natural physiology. | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. |
| Typical Dosage | CJC-1295 (no DAC/Mod GRF 1-29): 100-300mcg combined with Ipamorelin 200-300mcg, administered 1-3 times daily. Best results when administered fasted or before sleep. | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. |
| Administration | Subcutaneous injection. Often administered before bedtime to enhance natural nighttime GH release, or in the morning fasted. The combination is typically pre-mixed or injected simultaneously. | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. |
| Side Effects | Water retention, tingling in extremities, mild headaches, lightheadedness, or increased hunger. Generally well-tolerated with minimal effect on cortisol or prolactin. | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. |
| Best For |
What They Have in Common
Both CJC-1295 & Ipamorelin and Tirzepatide are commonly used for: